The heart in takayasu arteritis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__N)TOC__
__NOTOC__
{{SI}}
{{SI}}
{{CMG}}
{{CMG}}

Revision as of 16:58, 2 February 2015

WikiDoc Resources for The heart in takayasu arteritis

Articles

Most recent articles on The heart in takayasu arteritis

Most cited articles on The heart in takayasu arteritis

Review articles on The heart in takayasu arteritis

Articles on The heart in takayasu arteritis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on The heart in takayasu arteritis

Images of The heart in takayasu arteritis

Photos of The heart in takayasu arteritis

Podcasts & MP3s on The heart in takayasu arteritis

Videos on The heart in takayasu arteritis

Evidence Based Medicine

Cochrane Collaboration on The heart in takayasu arteritis

Bandolier on The heart in takayasu arteritis

TRIP on The heart in takayasu arteritis

Clinical Trials

Ongoing Trials on The heart in takayasu arteritis at Clinical Trials.gov

Trial results on The heart in takayasu arteritis

Clinical Trials on The heart in takayasu arteritis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on The heart in takayasu arteritis

NICE Guidance on The heart in takayasu arteritis

NHS PRODIGY Guidance

FDA on The heart in takayasu arteritis

CDC on The heart in takayasu arteritis

Books

Books on The heart in takayasu arteritis

News

The heart in takayasu arteritis in the news

Be alerted to news on The heart in takayasu arteritis

News trends on The heart in takayasu arteritis

Commentary

Blogs on The heart in takayasu arteritis

Definitions

Definitions of The heart in takayasu arteritis

Patient Resources / Community

Patient resources on The heart in takayasu arteritis

Discussion groups on The heart in takayasu arteritis

Patient Handouts on The heart in takayasu arteritis

Directions to Hospitals Treating The heart in takayasu arteritis

Risk calculators and risk factors for The heart in takayasu arteritis

Healthcare Provider Resources

Symptoms of The heart in takayasu arteritis

Causes & Risk Factors for The heart in takayasu arteritis

Diagnostic studies for The heart in takayasu arteritis

Treatment of The heart in takayasu arteritis

Continuing Medical Education (CME)

CME Programs on The heart in takayasu arteritis

International

The heart in takayasu arteritis en Espanol

The heart in takayasu arteritis en Francais

Business

The heart in takayasu arteritis in the Marketplace

Patents on The heart in takayasu arteritis

Experimental / Informatics

List of terms related to The heart in takayasu arteritis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Assistant Editor-in-Chief: Brian Blank

Synonyms and related keywords: Pulseless disease, non-specific aorto-arteritis, reverse coarctation, aortic arch syndrome, aortitis syndrome.

Overview

Cardiac complications of takayasu arteritis (TA) may include aortic regurgitation, myocarditis and congestive heart failure.

Pathophysiology and Classification

The classification scheme for late-phase Takayasu arteritis is based upon the site of involvement:

Type I

Classic pulseless type that involves the brachiocephalic trunk, carotid arteries, and subclavian arteries

Type II

Combination of type I and III

Type III

Atypical coarctation type that involves the thoracic and abdominal aorta distal to the aortic arch and its major branches

Type IV

Dilated type that involves extensive dilatation of the length of the aorta and its major branches

The most common type is type III, which is found in as many as 65% of patients. The most commonly involved vessels include the left subclavian artery (50%), left common carotid artery (20%), brachiocephalic trunk, renal arteries, celiac trunk, superior mesenteric artery, and pulmonary arteries (50%). Infrequently, the axillary, brachial, vertebral, coronary, and iliac arteries are involved.

Diagnosis

Initially, a diagnosis of TA can be missed for months or years because its symptoms can be nonspecific (fever, lethargy, etc.).

Physical Examination

While Takayasu arteritis is sometimes referred to as the "pulseless disease", it is important to note that a missing peripheral pulse usually occurs late in the course of TA. More often individuals with TA present with an asymmetric pulse.[1]

Imaging Studies

The diagnosis of TA is sometimes made when a widened mediastinum is noted on a chest x ray. A follow-up CT scan will often demonstrate a widened aortic arch. [1]

Computed Tomography and Magnetic Resonance Angiography

Computed Tomography (CT) and Magnetic Resonance Angiography (MRA) are the gold standrad imaging modalities for TA and may demonstrate mural thickening of the aorta and luminal narrowing. Use of contrast may reveal inflammatory lesions prior to the development of stenoses; these lesions may be missed by angiography. Aortic lesions including stenosis, dilatation, wall thickening, and mural thrombi are well visualized on MRI, which is less adequate in visualizing distal lesions of the subclavian vessels and common carotids. [2] Non-contrast T2-weighted STIR images may be used to monitor edema in the aortic wall, which may be a surrogate for inflammation; edema may present more than 94% of patients with clinically active disease. One disadvantage of MRA is that pressure differentials cannot be measured across lesions in which imaging findings regarding their hemodynamic significance are inconclusive.

Warning: Gadolinium-based contrast agents [gadopentetate dimeglumine (Magnevist), gadobenate dimeglumine (MultiHance), gadodiamide (Omniscan), gadoversetamide (OptiMARK), gadoteridol (ProHance)] have recently been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). The disease has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or MRA scans. In December 2006, the FDA had received reports of 90 such cases. Worldwide, over 200 cases have been reported, according to the FDA. NSF/NFD is a debilitating and sometimes fatal disease. Characteristics include red or dark patches on the skin; burning, itching, swelling, hardening, and tightening of the skin; yellow spots on the whites of the eyes; joint stiffness with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness. [3]

While computed tomography and MRA are the best imaging modalities, findings on other imaging modalities include:

Chest radiography

Chest radiographs may reveal widening of the ascending aorta, irregular descending aorta, aortic calcifications, and rib notching (late findings).

Duplex Doppler

This modality may be used to evaluate and monitor disease in the common carotids and subclavian arteries; however, this imaging study is not useful in evaluating the aorta.

Carotid Ultrasound

Carotid ultrasound demonstrates a homogenous circumferential thickening of the vessel wall that is distinguishable from atherosclerotic thickening.

Gallium-67 radionuclide scan

This scan may demonstrate increased uptake in the aorta and branches.

Prognosis

Five year survival in TA is over 90%, but TA is associated with significant morbidity.[1]

References

  1. 1.0 1.1 1.2 "Takayasu Arteritis: eMedicine Pediatrics: General Medicine".
  2. Yamada I, Nakagawa T, Himeno Y: Takayasu arteritis: diagnosis with breath-hold contrast-enhanced three- dimensional MR angiography. J Magn Reson Imaging 2000; 11: 481
  3. www.fda.gov



Template:WikiDoc Sources